Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has announced the pricing of an underwritten public offering of 2,802,272 shares of its common stock at a price to the public of US$110.00 per share, which consists of 2,727,272 shares to be sold by Twist and 75,000 shares to be sold by certain selling stockholders. The gross proceeds of the offering to Twist before deducting the underwriting discount and commissions and estimated offering expenses, and assuming no exercise of the underwriters’ option to purchase additional shares from the Company, are expected to be approximately US$300 million. Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares of common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on or about December 7, 2020, subject to the satisfaction of customary closing conditions. Twist will not receive any proceeds from the sale of common stock by the selling stockholders.
Latham & Watkins LLP represents the underwriters in the offering with a life sciences capital markets team led by Bay Area partner Brian Cuneo and Orange County partner Shayne Kennedy, with Bay Area associates Phillip Stoup, Casey Tong and Erica Chae, and Orange County associate Eric Hanzich. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu; on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with San Diego associate Robert Yeh, and Bay Area associate Peggy Ni.